CA2598510C - Q3 sparc deletion mutant and uses thereof - Google Patents

Q3 sparc deletion mutant and uses thereof Download PDF

Info

Publication number
CA2598510C
CA2598510C CA2598510A CA2598510A CA2598510C CA 2598510 C CA2598510 C CA 2598510C CA 2598510 A CA2598510 A CA 2598510A CA 2598510 A CA2598510 A CA 2598510A CA 2598510 C CA2598510 C CA 2598510C
Authority
CA
Canada
Prior art keywords
sparc
polypeptide
deletion mutant
nucleic acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2598510A
Other languages
English (en)
French (fr)
Other versions
CA2598510A1 (en
Inventor
Vuong Trieu
Neil P. Desai
Patrick Soon-Shiong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
Abraxis Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience LLC filed Critical Abraxis Bioscience LLC
Publication of CA2598510A1 publication Critical patent/CA2598510A1/en
Application granted granted Critical
Publication of CA2598510C publication Critical patent/CA2598510C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2598510A 2005-02-18 2006-02-17 Q3 sparc deletion mutant and uses thereof Expired - Fee Related CA2598510C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65426105P 2005-02-18 2005-02-18
US60/654,261 2005-02-18
PCT/US2006/005615 WO2006112930A2 (en) 2005-02-18 2006-02-17 Q3 sparc deletion mutant and uses thereof

Publications (2)

Publication Number Publication Date
CA2598510A1 CA2598510A1 (en) 2006-10-26
CA2598510C true CA2598510C (en) 2011-12-20

Family

ID=37000156

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2598510A Expired - Fee Related CA2598510C (en) 2005-02-18 2006-02-17 Q3 sparc deletion mutant and uses thereof

Country Status (7)

Country Link
US (3) US7332568B2 (https=)
EP (1) EP1869077A2 (https=)
JP (1) JP2008535475A (https=)
CN (1) CN101160321A (https=)
AU (1) AU2006237613A1 (https=)
CA (1) CA2598510C (https=)
WO (1) WO2006112930A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117862A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
CA2509365C (en) * 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
EP3527202A1 (en) * 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
LT3311805T (lt) 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
US8440625B2 (en) 2006-06-26 2013-05-14 University Of British Columbia Secreted protein acidic and rich in cysteine (SPARC) as chemotherapeutic sensitizers
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
WO2015081096A2 (en) * 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery
ES2389828T3 (es) * 2007-04-13 2012-11-02 Abraxis Bioscience, Inc. Composiciones que comprenden polipéptidos SPARC
EP2257626A2 (en) * 2008-03-01 2010-12-08 Abraxis BioScience, LLC Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
MX2010011165A (es) * 2008-04-10 2011-02-22 Abraxis Bioscience Llc Composiciones de derivados de taxano hidrofobos y sus usos.
JP2011516609A (ja) * 2008-04-14 2011-05-26 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー Ｓｐａｒｃ抗炎症活性及びその使用
AU2013228006B2 (en) * 2008-12-05 2016-05-12 Abraxis Bioscience, Llc Albumin binding peptide-mediated disease targeting
BRPI0922789A2 (pt) * 2008-12-05 2019-10-15 Abraxis Bioscience Llc peptídeo de ligação de albumina intermediador para reconhecimento de doença
BRPI0923155A2 (pt) * 2008-12-05 2018-10-23 Abraxis Bioscience Llc scfcs de ligação a sparc
WO2010105097A2 (en) * 2009-03-11 2010-09-16 Abraxis Bioscience, Llc Sparc angiogenic domain and methods of use
AU2010295324B2 (en) * 2009-09-18 2015-04-30 Abraxis Bioscience, Llc Use of the SPARC microenvironment signature in the treatment of cancer
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX2012013874A (es) 2010-06-03 2013-01-24 Abraxis Bioscience Llc Uso de la signatura en el microentorno de sparc en el tratamiento de cancer.
CA2801184A1 (en) * 2010-06-03 2011-12-08 Abraxis Bioscience, Llc Peripheral blood sparc binding antibodies and uses thereof
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270961B1 (en) * 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5128247A (en) * 1989-08-14 1992-07-07 Board Of Regents, The University Of Texas System Methods for isolation of nucleic acids from eukaryotic and prokaryotic sources
US5130423A (en) * 1990-07-13 1992-07-14 Microprobe Corporation Non-corrosive compositions and methods useful for the extraction of nucleic acids
CA2155186A1 (en) * 1993-02-01 1994-08-18 Kevin M. Ulmer Methods and apparatus for dna sequencing
KR960701988A (ko) * 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
US5945515A (en) * 1995-07-31 1999-08-31 Chomczynski; Piotr Product and process for isolating DNA, RNA and proteins
CA2278678A1 (en) * 1997-01-31 1998-08-06 Research Corporation Technologies, Inc. Cancer immunotherapy with semi-allogeneic cells
DE19740571C1 (de) * 1997-09-15 1999-03-18 Gsf Forschungszentrum Umwelt Verfahren zur Stimulation von T-Zellen mit gewünschter Antigenspezifität
US6316193B1 (en) * 1998-10-06 2001-11-13 Origene Technologies, Inc. Rapid-screen cDNA library panels
US20040018188A9 (en) 1999-01-20 2004-01-29 Incyte Genomics, Inc. Sparc-related proteins
US20020015950A1 (en) * 1999-07-07 2002-02-07 Karen Anne Jones Atherosclerosis-associated genes
US6387664B1 (en) * 1999-02-26 2002-05-14 Secretary Of Agency Of Industrial Science And Technology Sparc fusion protein and method for producing the same
ATE451835T1 (de) 1999-09-24 2010-01-15 Mayo Foundation Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
WO2001081631A1 (en) 2000-04-25 2001-11-01 Dna Sciences, Inc. Detection of nucleotide sequence variations via the proofreading activity of polymerases
WO2002090544A2 (en) 2001-05-04 2002-11-14 Hybrigenics Protein-protein interactions in adipocyte cells (3)
AU2003281325A1 (en) 2002-07-02 2004-01-23 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
US6919504B2 (en) * 2002-12-19 2005-07-19 3M Innovative Properties Company Flexible heat sink
WO2004064785A2 (en) * 2003-01-14 2004-08-05 Dana Farber Cancer Institute Cancer therapy sensitizer
JP2007525167A (ja) * 2003-04-01 2007-09-06 ジェンザイム・コーポレーション 乳房内皮細胞発現パターン
EP2784082B1 (en) 2004-05-14 2017-12-27 Abraxis BioScience, LLC Disease site-delivering pharmaceutical compositions comprising paclitaxel.

Also Published As

Publication number Publication date
CA2598510A1 (en) 2006-10-26
US7332568B2 (en) 2008-02-19
US20060199248A1 (en) 2006-09-07
EP1869077A2 (en) 2007-12-26
CN101160321A (zh) 2008-04-09
JP2008535475A (ja) 2008-09-04
US20110009337A1 (en) 2011-01-13
WO2006112930A3 (en) 2007-04-05
US20080182258A1 (en) 2008-07-31
WO2006112930A2 (en) 2006-10-26
AU2006237613A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
CA2598510C (en) Q3 sparc deletion mutant and uses thereof
CN102281890B (zh) Sparc结合肽及其应用
JP5496220B2 (ja) アルブミン結合ペプチド介在性の疾患標的化
AU2008240117B2 (en) SPARC and methods of use thereof
DK2081586T3 (en) RSPONDINES AS MODULATORS OF ANGIOGENESE AND VASCULOGENESES
US12415868B1 (en) Anti-NME antibody and method of treating cancer or cancer metastasis
KR20020073181A (ko) Ｌｉｖ-1 관련 단백질, 이를 코딩하는 폴리뉴클레오티드및 암의 치료를 위한 그의 용도
JP2023530039A (ja) 抗ｎｍｅ抗体および癌または癌転移の治療方法
JP2013542720A (ja) 抗エフリン−ｂ２抗体およびその使用
JPWO2005061704A1 (ja) 癌の予防・治療剤
WO2003029488A2 (en) A method for the early detection of cancer
AU2015201325B2 (en) Methods for diagnosing and treating cancers
EP1661990A1 (en) Polypeptide specific to liver cancer, polynucleotide encoding the polypeptide and rna molecule inhibiting the expression of the polypeptide
JP2003169683A (ja) 新規脱共役蛋白質ｍｔ００２９
AU2002329437A1 (en) A method for the early detection of cancer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140218